InflaRx N.V. Common Stock (IFRX)

Price$2.28

Value ScoreF

Growth ScoreF

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)92.77%

Price vs S&P 500 (4W)9.31%

VGM Score32.62

Market Capitalization$411.95M

All Metrics

Book Value / Share (Quarterly)$0.59

P/TBV (Annual)1.40x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.46

Price vs S&P 500 (YTD)126.69%

Gross Margin (TTM)-3693.72%

Net Profit Margin (TTM)-42170.98%

EPS (TTM)$-0.55

10-Day Avg Trading Volume1.11M

EPS Excl Extra (TTM)$-0.55

EPS (Annual)$-0.79

ROI (Annual)-107.39%

Gross Margin (Annual)-24678.79%

Cash / Share (Quarterly)$0.64

Revenue Growth QoQ (YoY)-80.75%

ROA (Last FY)-82.65%

Revenue Growth TTM (YoY)-51.41%

EBITD / Share (TTM)$-0.49

ROE (5Y Avg)-60.62%

Operating Margin (TTM)-35401.52%

Cash Flow / Share (Annual)$-0.57

P/B Ratio8.22x

P/B Ratio (Quarterly)1.50x

Net Income / Employee (Annual)$-818,173

EV / Revenue (TTM)4698.46x

Net Interest Coverage (TTM)-13.98x

ROA (TTM)-51.64%

EPS Incl Extra (Annual)$-0.79

Current Ratio (Annual)4.13x

Quick Ratio (Quarterly)3.88x

3-Month Avg Trading Volume1.23M

52-Week Price Return182.32%

Revenue / Employee (TTM)$1,165

Tangible BV / Share (Quarterly)$0.59

P/S Ratio (Annual)10336.31x

Asset Turnover (Annual)0.00x

52-Week High$2.95

EPS Excl Extra (Annual)$-0.79

CapEx CAGR (5Y)4.20%

Tangible BV CAGR (5Y)-11.74%

26-Week Price Return108.70%

Quick Ratio (Annual)3.88x

13-Week Price Return157.70%

Total Debt / Equity (Annual)0.02x

Current Ratio (Quarterly)4.16x

Enterprise Value$346.36M

Asset Turnover (TTM)0.00x

Book Value / Share Growth (5Y)-26.92%

Revenue / Employee (Annual)$583

Pretax Margin (Annual)-155545.52%

Cash / Share (Annual)$0.75

3-Month Return Std Dev111.15%

Net Income / Employee (TTM)$-578,583

ROE (Last FY)-109.81%

Net Interest Coverage (Annual)-5.86x

EPS Basic Excl Extra (Annual)$-0.79

Receivables Turnover (TTM)0.02x

Total Debt / Equity (Quarterly)0.02x

EPS Incl Extra (TTM)$-0.55

ROI (TTM)-68.27%

P/S Ratio (TTM)4792.35x

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.67

Price vs S&P 500 (52W)154.11%

Year-to-Date Return137.62%

5-Day Price Return-8.05%

EPS Normalized (Annual)$-0.79

ROA (5Y Avg)-48.80%

Net Profit Margin (Annual)-155587.38%

Month-to-Date Return15.94%

Cash Flow / Share (TTM)$-0.85

EBITD / Share (Annual)$-0.83

Operating Margin (Annual)-164539.45%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-59.62%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.55

P/TBV (Quarterly)1.50x

P/B Ratio (Annual)1.40x

Inventory Turnover (TTM)0.71x

Pretax Margin (TTM)-42151.56%

Book Value / Share (Annual)$0.67

Price vs S&P 500 (13W)147.96%

Beta2.45x

Revenue / Share (TTM)$0.00

ROE (TTM)-69.50%

52-Week Low$0.74

vGradeF

gGradeF

mGradeB

vgmGradeD

Show chart for

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.07

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
IFRXInflaRx N.V. Common Stock	F	F	B	$2.28
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
ABTAbbott Laboratories	C	C	D	$87.78
PFEPfizer Inc.	B	C	C	$25.63
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

InflaRx NV is a clinical-stage biopharmaceutical company developing targeted therapies for autoimmune and inflammatory diseases. The company's lead candidate, vilobelimab, is a first-in-class monoclonal antibody designed to inhibit C5a, a key inflammatory mediator implicated in multiple disease pathways. Clinical data has demonstrated disease-modifying activity and a favorable safety profile. The company is advancing this platform with plans to address multiple therapeutic indications.